<?xml version="1.0" encoding="UTF-8" standalone="yes"?><?xml-stylesheet type="text/xsl" href="/oai-pmh-repository/static/oai2.xsl"?>
<OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd">
    <responseDate>2026-10-15T12:16:18Z</responseDate>
    <request verb="GetRecord" identifier="oai:data.mendeley.com/f6vytp24ny.1" metadataPrefix="oai_dc">https://data.mendeley.com/oai</request>
    <GetRecord>
        <record>
            <header>
                <identifier>oai:data.mendeley.com/f6vytp24ny.1</identifier>
                <datestamp>2019-09-11T16:53:54Z</datestamp>
            </header>
            <metadata><oai_dc:dc xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd" xmlns:oai_dc="http://www.openarchives.org/OAI/2.0/oai_dc/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <dc:creator>Trabattoni, Daniela</dc:creator>
    <dc:title>Xience stent single-center registry</dc:title>
    <dc:publisher>Mendeley Data</dc:publisher>
    <dc:description>ABSTRACT 
Background: Safety and effectiveness of the everolimus-eluting stent (EES) have been previously demonstrated. 
Aims: To assess very long-term performance and outcomes of the EES in a real-world population. Methods: This single-center registry prospectively enrolled 6,893 patients (mean age 66±9.7 years, 81.4% men) undergoing elective coronary intervention with the  EES over a decade. Clinical follow-up (FU) was performed at 1 year and then yearly. 
Results: Multiple risk factors were present in 34%. Stable angina was the main stenting indication (78.1%), followed by unstable angina (5.3%) and positive stress test (16.6%) for 1- (44%) or 2/3-VD (56%). Multiple stents (stent/patient ratio: 2.1±0.8) in &gt;1vessel were implanted in 36.9% (mean stent length=43±31.3 mm). At 1 year, 80% of patients were on dual antiplatelet therapy, while 3% only at 2 years. A low (5%) 1-year MACE rate was observed; ST occurred in 19 (0.3%) patients with a prevalence of early (9) over late (4) and very late (6) (0.08%) events. Clinically driven TLR/TVR occurred in 3.3% at 1-year follow-up. Long-term FU (3 years) completed in 6210 (90%) patients showed a 5.9% MACE rate, while very long-term (&gt;5 years and up to 10 years) follow-up, available in 3550 out of 4635 exposed patients (72%), showed an 8.6% MACE rate. Independent MACE predictors were stented segment length (OR: 2.1; 95% CI:1.57-2.82), small vessel stenting (OR: 1.34;95% CI: 1.08-1.68) and multivessel disease (2VD, OR:1.59; 95%  CI: 1.21-2.08; 3VD, OR: 2.26; 95% CI: 1.72-2.97). 
Conclusions: This large prospective registry confirms the very long-term safety and efficacy of the EES in unselected real world and complex coronary lesions.
</dc:description>
    <dc:subject>Interventional Cardiology</dc:subject>
    <dc:type>Dataset</dc:type>
    <dc:identifier>doi:10.17632/f6vytp24ny.1</dc:identifier>
    <dc:identifier>oai:data.mendeley.com/f6vytp24ny.1</dc:identifier>
    <dc:rights>Creative Commons Attribution 4.0 International</dc:rights>
    <dc:rights>http://creativecommons.org/licenses/by/4.0</dc:rights>
    <dc:relation>https://data.mendeley.com/datasets/f6vytp24ny</dc:relation>
    <dc:date>2019-09-11T16:53:54Z</dc:date>
</oai_dc:dc></metadata>
        </record>
    </GetRecord>
</OAI-PMH>
